Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $23.8 million.

  • NewAmsterdam Pharma's Other Non Operating Income rose 40815.89% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year decrease of 72.96%. This contributed to the annual value of $38.6 million for FY2024, which is 28513.68% up from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Other Non Operating Income of $23.8 million as of Q3 2025, which was up 40815.89% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Other Non Operating Income peaked at $30.2 million during Q1 2024, and registered a low of -$13.8 million during Q1 2025.
  • Over the past 3 years, NewAmsterdam Pharma's median Other Non Operating Income value was $4.7 million (recorded in 2024), while the average stood at $7.0 million.
  • The largest annual percentage gain for NewAmsterdam Pharma's Other Non Operating Income in the last 5 years was 88624.06% (2024), contrasted with its biggest fall of 906111.11% (2024).
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Other Non Operating Income stood at $10.2 million in 2023, then surged by 92.33% to $19.6 million in 2024, then rose by 21.54% to $23.8 million in 2025.
  • Its Other Non Operating Income stands at $23.8 million for Q3 2025, versus $8.6 million for Q2 2025 and -$13.8 million for Q1 2025.